Read This Before Investing in LLY

Eli Lilly and Company logged a -1.9% change during today's afternoon session, and is now trading at a price of $344.25 per share. The S&P 500 index moved 0.8%. LLY's trading volume is 1,932,731 compared to the stock's average volume of 2,803,172.

Eli Lilly and Company trades -11.62% away from its average analyst target price of $389.52 per share. The 23 analysts following the stock have set target prices ranging from $268 to $440, and on average have given Eli Lilly and Company a rating of buy.

Anyone interested in buying LLY should be aware of the facts below:

  • Eli Lilly and Company's current price is 720.1% above its Graham number of $41.98, which implies that at its current valuation it does not offer a margin of safety

  • Eli Lilly and Company has moved 44.4% over the last year, and the S&P 500 logged a change of -11.3%

  • Based on its trailing earnings per share of 6.65, Eli Lilly and Company has a trailing 12 month Price to Earnings (P/E) ratio of 51.8 while the S&P 500 average is 15.97

  • LLY has a forward P/E ratio of 41.6 based on its forward 12 month price to earnings (EPS) of $8.27 per share

  • The company has a price to earnings growth (PEG) ratio of 2.54 — a number near or below 1 signifying that Eli Lilly and Company is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 30.8 compared to its sector average of 4.07

  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.

  • Based in Indianapolis, the company has 35,000 full time employees and a market cap of $327,098,761,216. Eli Lilly and Company currently returns an annual dividend yield of 1.1%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.